Randomized phase III trial results of Panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer

Tara Beers Gibson, Aarati Ranganathan, Axel Grothey

Research output: Contribution to journalReview article

134 Scopus citations

Abstract

Monoclonal antibodies against the epidermal growth factor receptor have proven efficacy as monotherapy and in combination with chemotherapy in patients with metastatic colorectal cancer (CRC; mCRC). Initial clinical trials in CRC used the human-murine chimeric monoclonal antibody cetuximab. Ongoing studies are being conducted to evaluate the efficacy and safety of the fully human anti-epidermal growth factor receptor monoclonal antibody panitumumab. The results of a phase III trial, which compared panitumumab as a single agent to best supportive care in patients with previously treated metastatic CRC, have recently been reported. Panitumumab therapy resulted in a 46% reduction in the risk of tumor progression and a partial response rate of 8%. Rash was reported in 90% of patients, with increased severity significantly correlated with improved median overall survival (OS). Further clinical studies are ongoing and planned to test panitumumab in combination with chemotherapy in first-line therapy of advanced-stage CRC and adjuvant treatment of colon cancer.

Original languageEnglish (US)
Pages (from-to)29-31
Number of pages3
JournalClinical colorectal cancer
Volume6
Issue number1
DOIs
StatePublished - May 2006

Keywords

  • Best supportive care
  • Skin-related toxicities
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Randomized phase III trial results of Panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer'. Together they form a unique fingerprint.

  • Cite this